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ABSTRACT:
The Mdm2 oncoprotein promotes p53 ubiquitination and destruction. Yet, exact 
molecular mechanisms of Mdm2 destruction itself, under DNA damaging conditions, 
remain unclear. Recently, we identified SCFβ-TRCP as a novel E3 ligase that targets Mdm2 
for ubiquitination and destruction in a Casein Kinase Iδ (CKIδ)-dependent manner. 
However, it remains elusive how the β-TRCP/CKIδ/Mdm2 signaling axis is regulated 
by DNA damage signals to govern p53 activity. Consistent with previous studies, we 
found that inactivation of the Ataxia Telangiectasia Mutated (ATM) kinase, in turn, 
impaired DNA damage-induced Mdm2 destruction. Although phosphorylation of Mdm2 
at Ser395 (an ATM phosphorylation site) facilitated Mdm2 interaction with β-TRCP, 
Ser395A-Mdm2 was degraded non-distinguishably from WT-Mdm2 by SCFβ-TRCP upon 
DNA damaging treatments. This indicates that in addition to phosphorylating Mdm2 
at Ser395, ATM may govern Mdm2 stability through other unknown mechanisms. 
We further demonstrated that DNA damage-induced activation of ATM directly 
phosphorylated CKIδ at two well-conserved S/TQ sites, which promotes CKIδ nuclear 
localization to increase CKIδ-mediated phosphorylation of Mdm2, thereby facilitating 
subsequent  Mdm2  ubiquitination  by  SCFβ-TRCP. Our studies provide a molecular 
mechanism of how ATM could govern DNA damage-induced destruction of Mdm2 in 
part by phosphorylating both Mdm2 and CKIδ to modulate SCFβ-TRCP–mediated Mdm2 
ubiquitination. Given the pivotal role of Mdm2 in the negative regulation of p53, this 
work will also provide a rationale for developing CKIδ or ATM agonists as anti-cancer 
agents.
INTRODUCTION 
Human cancer development has been characterized 
to be a multi-step process that is associated with both 
activation of multiple oncogenes and inactivation of 
various tumor suppressor genes [1]. The p53 gene is 
considered as one of the prototypical tumor suppressor 
gene, as abnormalities of the p53 gene have been observed 
in more than half of all human cancers [2]. The p53 tumor 
suppressor protein plays a critical role in anti-proliferation 
activity through inducing cell cycle arrest, senescence, and 
programmed cell death [3]. Additionally, p53 has been 
reported to have a physiological function in regulating 
cellular responses to DNA damage in part by inducing 
either G1 or G2 checkpoints, allowing sufficient time for 
cells to repair their damaged DNA [4]. Recent studies 
have also shown that p53 is involved in governing the 
cellular apoptotic pathway under conditions when cells 
are exposed to excessive DNA damage beyond the ability 
of cells to efficiently repair them [4]. Given the pivotal 
roles of p53 in various cellular processes, p53 activity is 
tightly regulated at multiple levels including transcription, 
translation and protein stability [5]. Although several 
E3 ubiquitin ligases including Mdm2 [6], E6AP [7], Oncotarget 2012; 3: 1026-1035 1027 www.impactjournals.com/oncotarget
TOPORS [8] , RFFL [9], Cop1 [10] and Pirh2 [11] have 
been implicated in regulating p53 stability, mouse genetic 
studies strongly indicate that Mdm2 (mouse double 
minute 2) [12, 13] is the major negative regulator for p53 
stability [6]. Consistent with the critical role of Mdm2 
as the major physiological E3 ligase in promoting p53 
destruction, the Mdm2 oncoprotein is frequently found 
to be overexpressed in a wide variety of human cancers 
[14]. Furthermore, mutations in the Mdm2 oncoprotein 
that disrupt ribosomal protein (RP)-mediated suppression 
of Mdm2 E3 ligase activity have been observed in human 
cancers [15]. In line with the critical role for Mdm2-
mediated degradation of p53 in favoring tumorigenesis, 
a specific Mdm2 inhibitor (MI-219) has been reported to 
synergize with oxaliplatin, which inhibits DNA synthesis, 
to exhibit superior anti-cancer effects in solid tumors types 
bearing wild-type p53 [16]. 
However, the exact molecular mechanisms 
underlying Mdm2 overexpression in human cancers 
remain  largely  elusive.  We  recently  identified  that 
both cell cycle regulated and DNA damage-induced 
turnover of Mdm2 is controlled by SCFβ-TRCP-mediated 
ubiquitination of Mdm2 [17, 18]. We further defined a 
critical role for Casein Kinase Iδ (CKIδ) in SCFβ-TRCP-
mediated degradation of Mdm2 [17, 18]. Importantly, 
depletion of β-TRCP resulted in attenuated p53 activity, 
reduced pulsatile waves of p53 in response to persistent 
DNA damage, and increased resistance to DNA damage-
induced apoptosis [18]. However, it remains largely 
uncharacterized how DNA damaging signals control 
β-TRCP-mediated Mdm2 destruction. Furthermore, even 
though CKIδ kinase was identified to play a critical role in 
mediating cell cycle-dependent destruction of Mdm2 by 
SCFβ-TRCP [17, 18], it is not fully understood whether under 
the DNA damage conditions, the CKIδ kinase is activated 
to govern the Mdm2/p53 pathway.
To this end, multiple studies have demonstrated that 
the ATM (ataxia telangiectasia mutated) tumor suppressor 
protein can regulate Mdm2 under genotoxic stresses [19-
21]. ATM is one of the founding members of the PIKK 
(phosphatidyl inositol 3-kinase related kinase) family 
of kinases [22]. In response to DNA damage caused by 
UV exposure or reactive oxygen species (ROS), ATM is 
activated, which subsequently leads to the phosphorylation 
of p53. ATM-mediated phosphorylation of p53 disrupts 
the binding between Mdm2 and p53, resulting in enhanced 
p53 stability by escaping Mdm2-mediated ubiquitination 
[20]. In addition to p53, Mdm2 was also reported to 
undergo ATM-dependent phosphorylation on the Serine 
395 (Ser395) residue in response to DNA damage [23]. 
Importantly, transgenic mice studies revealed that ATM 
phosphorylation of Mdm2 at Ser394 (equivalent to human 
Ser395 site) is required for p53 stabilization and activation 
after DNA damage [24]. These studies prompted us to 
further study whether the ATM kinase plays a critical role 
in SCFβ-TRCP-mediated Mdm2 proteolysis following DNA 
damaging signals.
In the present study, for the first time, we report 
that ATM indeed participates in β-TRCP-mediated Mdm2 
ubiquitination and destruction. Moreover, our results 
demonstrate that phosphorylation of Mdm2 by ATM at 
Ser395  is  not  necessary  for  β-TRCP-mediated  Mdm2 
ubiquitination after DNA damage. On the other hand, 
ATM-dependent phosphorylation of CKIδ promotes CKIδ 
nuclear  localization  to  trigger  CKIδ-mediated  Mdm2 
phosphorylation and subsequent destruction. Hence, our 
current study supports the critical role of ATM in SCFβ-
TRCP–mediated Mdm2 degradation. Furthermore, our 
results suggest that ATM agonists could be used as anti-
cancer agents, in part by accelerating Mdm2 destruction. 
Figure 1: ATM is involved in DNA damage-induced Mdm2 destruction. (A) Immunoblot analysis of HeLa cells transfected with 
the indicated shRNA constructs. Cells were treated with the indicated concentrations of the ATM inhibitor for 12 hours before harvesting. 
(B) Endogenous ATM expression was depleted in U2OS cells by infecting with the indicated lentiviral shRNA constructs (with shGFP as a 
negative control) and selected with 1 µg/ml puromycin to eliminate the non-infected cells. The resulting U2OS cell lines were treated with 
etoposide or neocarzinostatin (NCS) for the indicated durations to induce Mdm2 destruction before harvesting for immunoblot analysis.Oncotarget 2012; 3: 1026-1035 1028 www.impactjournals.com/oncotarget
RESULTS
Mdm2 E3-ligase activity is not required for DNA 
damage-induced Mdm2 destruction
Consistent with previous reports [18], we found 
that in multiple cell lines, the Mdm2 oncoprotein became 
more unstable following DNA damaging agent, such as 
etoposide treatment (Supplemental Figures 1A-B). Studies 
from multiple laboratories have indicated that DNA-
Figure 2: ATM-mediated phosphorylation of Mdm2 is not critical for Mdm2 destruction. (A) Schematic illustration of 
the biotinylated Mdm2 peptides used in this study.  (B) Autoradiography of 35S-labeled β-TRCP1 bound to the indicated biotinylated 
peptides. (C) Casein Kinase Iδ phosphorylates Mdm2 at multiple sites to trigger Mdm2 destruction mediated by β-TRCP1. Immunoblot 
analysis of U2OS cells transfected with the indicated HA-Mdm2 and Flag-β-TRCP1 plasmids. A plasmid encoding GFP was used as a 
negative control for transfection efficiency. Thirty hours post-transfection, 25 µM etoposide was used for up to three hours to trigger 
Mdm2 destruction before harvesting cells for immunoblots. (D) Schematic illustration of the various Mdm2 deletion mutants. p1, p2 and 
p3 are three identified PEST-sequence containing motifs that contain the identified CKI-phosphorylation sites. Loss of p1, p2, p3 creates 
a non-degradable mutant of Mdm2 (∆p1p2p3). C464A mutant form of Mdm2 lacks the E3 ubiquitin ligase activity, thus is defective in 
undergoing self-ubiquitination. (E) Immunoblot analysis of 293T cells transfected with HA-Mdm2 and the indicated shRNA constructs, 
after synchronization with nocodazole and release.Oncotarget 2012; 3: 1026-1035 1029 www.impactjournals.com/oncotarget
damage could possibly augment Mdm2 auto-degradation 
[25, 26]. However, a recent study demonstrated that the 
E3-ligase activity of Mdm2 might not be required for 
its destruction [27]. To solve this potential discrepancy, 
we continued to explore whether a Ring-finger mutant 
Mdm2C464A that is defective in its E3 ubiquitin ligase 
activity, also became unstable upon DNA damaging 
treatments. In line with previous reports [18, 27], we 
found that Mdm2C464A becomes unstable after treatment 
with a variety of DNA damaging agents including 5-FU, 
Doxorubicin, Actinomycin D (Supplemental Figures 
1C-E). These results suggest that E3 ligase(s) other than 
Mdm2 itself, such as recently identified β-TRCP [18], 
might govern Mdm2 destruction under DNA damage 
Figure 3: ATM phosphorylates Casein Kinase Iδ to regulate its subcellular localization and its ability to interact 
with Mdm2. (A) Protein sequence illustration of the two putative ATM phosphorylation sites present in the C-terminus of CKIδ across 
different species. Hyd: hydrophobic amino acids. (B) Immunoblot analysis (IB) of whole cell lysates (WCL) and immunoprecipitates (IP) 
derived from 293T cells transfected with the indicated GST-CKIδ constructs in the presence or absence of Flag-ATM. Where indicated, 
the ATM kinase was activated by treatment with etoposide for 30 minutes before harvesting. The phosphorylation status of CKIδ by ATM 
in vivo was detected with a specific phospho-(S/T) ATM substrate antibody. (C) ATM phosphorylates both Mdm2 and CKIδ in vitro. The 
ATM kinase was purified by Flag-immunoprecipitation from 293T cells, and then incubated with 5 µg of GST-Mdm2 or the indicated 
GST-CKIδ proteins (with GST protein as a negative control) in the presence of γ-32P-ATP. The kinase reaction products were resolved 
by SDS-PAGE and phosphorylation was detected by autoradiography. (D) Immunoblot (IB) analysis of whole cell lysates (WCL) and 
immunoprecipitates (IP) derived from 293T cells transfected with HA-Mdm2 and the indicated GST-CKIδ constructs. Thirty hours post-
transfection, cells were pretreated with 10 µM MG132 for 2 hours to block the proteasome pathway and then treated with 25 µM etoposide 
(or DMSO as control) for 1.5 hours before harvesting.Oncotarget 2012; 3: 1026-1035 1030 www.impactjournals.com/oncotarget
conditions. However, mechanistically, it remains largely 
unknown how DNA damaging signals are transduced 
to  possibly  control  β-TRCP-mediated  ubiquitination 
of  Mdm2. As  most  β-TRCP  substrates  require  prior-
phosphorylation for recognition by β-TRCP [28], it is 
critical to reveal the upstream signaling pathway(s) that 
are activated by DNA damage to trigger β-TRCP-mediated 
timely destruction of Mdm2.
ATM is involved in DNA damage-induced Mdm2 
destruction
Given the pivotal role of ATM in DNA damage 
response, we started our investigation by examining 
whether ATM participates in Mdm2 stability control. 
In keeping with our previous report [18], depletion of 
both  isoforms  of  endogenous  β-TRCP  (β-TRCP1  and 
β-TRCP2) led to a significant increase of Mdm2 protein 
Figure 4: ATM-mediated phosphorylation of CK1δ promotes CK1δ  localization, and subsequent phosphorylation 
of Mdm2 to trigger Mdm2 degradation. (A) ATM-mediated  phosphorylation  of  CK1δ  promotes  CK1δ  nuclear  localization. 
Immunofluorescence and DAPI staining of U2OS cells transfected with the indicated Myc-CKIδ constructs. Cells were treated with or 
without 10µM doxorubicin for 1 hour before fixation. (B) Stability of the Mdm2 protein is controlled by ATM. U2OS cells were infected 
with the indicated lentiviral shRNA construct and selected with 1 µg/ml puromycin to eliminate the non-infected cells. The resulting 
U2OS cell lines were transfected with the indicated HA-Mdm2, Flag-β-TRCP1 and Myc-CKIδ constructs. Immunoblots were performed 
to monitor the changes of HA-Mdm2. p1 and p2 are two of the three identified major PEST-sequence containing motifs that contain the 
identified CKI-phosphorylation sites.Oncotarget 2012; 3: 1026-1035 1031 www.impactjournals.com/oncotarget
abundance (Figure 1A). More interestingly, inactivation of 
ATM kinase by its pharmaceutical inhibitor [16, 29], led to 
a dose-dependent increase in Mdm2 abundance as well in 
shGFP-treated control HeLa cells (Figure 1A). However, 
ATM inhibitor could not induce Mdm2 expression in 
shβ-TRCP-treated HeLa cells, indicating that ATM might 
govern Mdm2 stability in a β-TRCP-dependent manner. 
Notably, consistent with previous reports [30-32], 
depletion of endogenous ATM with multiple independent 
shRNA vectors moderately affected Mdm2 destruction 
in response to various DNA damaging agents (Figure 
1B). These results indicate a possible role for the ATM 
signaling pathway in regulating DNA damage-induced 
Mdm2 destruction. The next critical question we intended 
to address is to determine which is the major downstream 
signaling route through which DNA damage-induced 
activation of ATM influences Mdm2 stability.
ATM-mediated phosphorylation of Mdm2 is not 
critical for Mdm2 destruction
As Mdm2 has been reported to be phosphorylated 
by ATM at the Ser395 site, we continued our study by 
examining whether direct phosphorylation of Mdm2 
by ATM affects Mdm2 interaction with its E3 ligase, 
β-TRCP1.  Using  immobilized  biotinylated  Mdm2 
peptides derived from the range spanning the identified 
ATM phosphorylation site (Ser395) (Figure 2A), we found 
that a phosphorylation event occurring at Ser395 could 
trigger Mdm2 interaction with β-TRCP1 (Figure 2B). 
It is thus possible that ATM-phosphorylation on Ser395 
in Mdm2 may prime for the subsequent CKI-mediated 
phosphorylation. However, we found that mutation of 
the Ser395 site did not affect etoposide-induced Mdm2 
destruction (Figures 2C-D). Furthermore, overexpression 
of  ATM  alone  failed  to  significantly  trigger  Mdm2 
destruction, or to promote Mdm2 ubiquitination in vitro 
(data not shown), indicating that ATM may require other 
kinase(s) to synergistically regulate Mdm2 degradation. 
Since our previous studies identified CKIδ as an upstream 
kinase responsible for Mdm2 destruction (Figure 2E) [18], 
it was thus of great interest for us to further investigate 
whether ATM promotes Mdm2 degradation mainly by 
influencing CKIδ-mediated phosphorylation of Mdm2. 
Figure 5: A proposed role for the ATM in β-TRCP-mediated Mdm2 ubiquitination and destruction. Oncotarget 2012; 3: 1026-1035 1032 www.impactjournals.com/oncotarget
ATM phosphorylates CKIδ to possibly regulate its 
ability to interact with, and subsequently promote 
Mdm2 destruction
 Although CKI has been reported to be activated by 
DNA damage in Drosophila cells [33], the exact molecular 
mechanisms of how CKI is activated following DNA 
damaging treatment in human cells are largely unknown. 
Upon  subsequent  examination  of  the  CKIδ  protein 
sequence, we found two well-conserved potential ATM 
phosphorylation [34] sites in its regulatory domain (Figure 
3A). In keeping with this finding, we found that ATM 
could phosphorylate CKIδ (Figures 3B-C) to potentially 
regulate its ability to interact with Mdm2 (Figure 3D). As 
a result, etoposide treatment, which activates ATM kinase, 
promotes CKIδ and Mdm2 interaction while the CKIδ 
mutant (CKIδ-T337A/S398A), where the two conserved 
ATM sites were inactivated, failed to interact with Mdm2 
upon etoposide treatment (Figure 3D). 
ATM-mediated  phosphorylation  of  CK1δ 
promotes CK1δ nuclear localization
To further understand the molecular mechanisms 
underlying how DNA damaging signals may potentially 
regulate  CKIδ  activity,  we  immunoprecipitated  CKIδ 
from U2OS cells after treatment with etoposide for the 
indicated time periods to measure its kinase activity. The 
CKIδ activity changes were indicated by its ability to 
phosphorylate recombinant Skp2 or CKIδ itself in vitro. 
Surprisingly, we only detected a moderate increase in the 
intrinsic CKIδ kinase activity in response to DNA damage   
(Supplemental Figures S2A-B). These results indicate that 
rather than directly regulating the CKIδ kinase activity, 
DNA damaging signals might influence the association of 
CKIδ with its substrates including Mdm2 by controlling 
CKIδ  cellular  localization.  In  support  of  this  notion, 
we found that in agreement with a previous report [35], 
CKIδ mainly resides in the cytoplasm in non-stressed 
cells. However, in response to DNA damage, a significant 
fraction of endogenous CKIδ translocated into the nucleus 
to interact with, and modify, the Mdm2 protein (Figure 
4A). More importantly, we showed that inactivation 
of the two putative ATM sites, which are located at the 
C-terminus  of  CKIδ,  disrupts  its  ability  to  enter  the 
nucleus following DNA damage (Figure 4A). This result 
strongly suggests that ATM plays an important role in 
DNA damage-induced nuclear translocation of CKIδ  to 
promote CKIδ-mediated Mdm2 phosphorylation, which 
might  influence  the  subsequent  Mdm2  ubiquitination 
and destruction mediated by the β-TRCP/CKIδ signaling 
axis. Furthermore, in support of a critical role of ATM 
in  β-TRCP/CKIδ−mediated  Mdm2  destruction,  we 
found that depletion of endogenous ATM attenuated the 
destruction  of  ectopically  expressed  WT-Mdm2,  ∆p1-
Mdm2 or ∆p2-Mdm2 after co-expression of both β-TRCP 
and CKIδ (Figure 4B). On the other hand, consistent with 
our previous report [18], depleting all possible β-TRCP-
recognizable  degrons  containing  the  identified  CKIδ 
phosphorylation sites created a non-degradable Mdm2 
(∆p1p2p3-Mdm2)  that  resists  the  destruction  effects 
mediated by co-expressing β-TRCP and CKIδ (data not 
shown). These results elucidated the specificity of this in 
vivo degradation assay, and further implicated that CKIδ-
dependent phosphorylation events is the major signaling 
route through which DNA damage-dependent activation 
of ATM might control timely turnover of Mdm2 during 
genotoxic stress. 
DISCUSSION
Cells have complex mechanisms to protect their 
genomes from various endogenous and exogenous 
stressors including UV exposure, γ-irradiation, ROS, and 
mutagens, which cause DNA damage [36]. For example, 
cells have multiple repair mechanisms and checkpoint 
responses to maintain their genomic stability. DNA 
damage responses are governed by multiple signaling 
pathways including the ATM-Chk2 and ATR-Chk1 
pathways [37]. It has been reported that DNA damage 
leads to ATM-dependent USP7S (a specific isoform of 
USP7) dephosphorylation by PPM1G (protein phosphatase 
magnesium-dependent 1 gamma), thus resulting in the 
inactivation and degradation of USP7S to promote Mdm2 
ubiquitination and degradation [38]. Although activation 
of ATM has been found to be crucial for DNA damage 
responses, the underlying molecular mechanisms are 
largely unknown. Here we report that DNA damage 
activates ATM, which subsequently phosphorylates 
CKIδ to promote its translocation into the nucleus where 
phosphorylation of Mdm2 by CKIδ ultimately triggers 
Mdm2 degradation by SCFβ-TRCP (Figure 5). 
It has been shown that the inhibitory function of 
Mdm2 towards p53 plays a major role in modulating 
p53 activity following DNA damage, a process that is 
subjected to many layers of regulation [39]. Among them, 
the ATM/ATR/Chk kinase cascade induced by DNA 
damage has an important function in the regulation of 
p53 activity in part by directly phosphpryating p53 [40]. 
Inhibition of ATM resulted in p53 shift from the nuclear 
to cytosolic fractions, which inactivates its transcriptional 
activity [41]. Furthermore, ATM has been demonstrated 
to phosphorylate Mdm2 at Ser395 [23]. Mechanistically, 
ATM phosphorylation of Mdm2 inhibits the ability of 
Mdm2 to poly-ubiquitinate p53, thereby resulting in p53 
stabilization [42]. This prompted us to explore whether 
ATM participates in Mdm2 stability control. Indeed, we 
found that the use of an ATM inhibitor increased Mdm2 
abundance in control HeLa cells, but not in β-TRCP-
depleted HeLa cells, suggesting that ATM could govern 
Mdm2 stability in a β-TRCP-dependent manner. However, Oncotarget 2012; 3: 1026-1035 1033 www.impactjournals.com/oncotarget
inactivating Ser395 in Mdm2 did not significantly stabilize 
Mdm2 under DNA damaging conditions, arguing that 
ATM may control Mdm2 turnover by phosphorylating 
other critical components of the Mdm2 destruction 
pathway. In support of this notion, we found that in 
response to DNA damage, activation of the ATM kinase 
directly phosphorylates CKIδ at its C-terminus to regulate 
its subcellular localization and interaction with Mdm2 
(Figure 3A). These data indicate that DNA damage 
primarily modulates the accessibility of CKIδ cellular 
localization (Figure 4A) rather than its kinase activity 
(Supplemental  Figures  S2A-B)  to  influence  Mdm2 
stability. 
On the basis of our results, we propose a 
hypothetical model by which ATM is the upstream kinase 
that following activation by DNA damaging signals, could 
phosphorylate CKIδ to potentially regulate its subcellular 
localization and its ability to interact with and regulate 
Mdm2 (Figure 5). However, we recognize that ATM may 
also phosphorylate other unknown substrates to affect 
Mdm2 turnover. Therefore, further in-depth studies are 
needed to investigate the precise molecular mechanism 
of how ATM affects CKIδ cellular localization, as well 
as how ATM and CKIδ work synergistically to promote 
Mdm2 destruction following DNA damage. In summary, 
we presented experimental evidence that strongly supports 
the pivotal roles of ATM in β-TRCP-mediated Mdm2 
degradation. Since ATM and CK1 synergistically control 
β-TRCP-mediated Mdm2 ubiquitination and destruction, 
our work provides a rational for the use of CKI and/or 
ATM agonists as anti-cancer agents to promote Mdm2 
destruction, which might improve the overall survival of 
patients diagnosed with cancer in the future. 
MATERIALS AND METHODS
Plasmids 
HA-Mdm2 construct was kind gift from Dr. Jiandong 
Chen. Various Mdm2 and CKIδ mutants were generated 
using the QuikChange XL Site-Directed Mutagenesis Kit 
(Stratagene) according to the manufacturer’s instructions. 
The  C-terminus  fragment  (aa  285-415)  of  CKIδ  was 
subcloned using the Pfu polymerase (Stratagene) into 
the pGEX vector to create GST-CKIδ in frame fusion 
proteins. Flag-β-TRCP1, shRNA-β-TRCP1+2, shTRCP1, 
shTRCP2, and shRNA-GFP constructs were described 
previously [43, 44]. Flag-ATM construct was obtained 
from Michael Kastan. shRNA constructs against various 
CKI isoforms were obtained from Dr. Jianping Jin. 
Lentiviral shRNA constructs against GFP, ATM and CKIδ 
were obtained from Dr. William Hahn.
Antibodies and Reagents
Anti-cyclin A (SC-751), anti-cyclin B (SC-245), 
anti-cyclin  E  (SC-247),  anti-Casein  Kinase  Iδ  (R-19) 
(SC-6474) and polyclonal anti-HA (SC-805) antibodies 
were purchased from Santa Cruz. Polyclonal anti-FLAG 
(F2425), monoclonal anti-FLAG (F-3165), peroxidase-
conjugated anti-mouse secondary antibody (A4416), 
peroxidase-conjugated anti-rabbit secondary antibody 
(A4914), and Anti-tubulin (T-5168) antibodies were 
purchased from Sigma. Monoclonal anti-HA antibody 
(MMS-101P) was purchased from Covance. The anti-
GFP (632380) antibody was purchased from Invitrogen. 
The anti-phospho-Ser1981 ATM (4526) antibody was 
purchased from Cell Signaling. Anti-Mdm2 (Ab1:OP46) 
was purchased from Calbiochem. Oligofectamine, 
Lipofectamine and Plus reagents were purchased from 
Invitrogen.
Immunoblots and Immunoprecipitation
Cells were lysed in EBC (50 mM Tris pH 8.0, 
120 mM NaCl, 0.5% NP-40) buffer supplemented 
with protease inhibitors (Complete Mini, Roche) and 
phosphatase inhibitors (phosphatase inhibitor cocktail 
set I and II, Calbiochem). The protein concentrations 
of the lysates were measured using the Bio-Rad 
protein assay reagent on a Beckman Coulter DU-800 
spectrophotometer. The lysates were then resolved by 
SDS-PAGE and immunoblotted with indicated antibodies. 
For immunoprecipitation, 800 µg lysates were incubated 
with the appropriate antibody (1-2 g) for 3-4 hours at 4 C 
followed by one hour-incubation with Protein A sepharose 
beads (GE Healthcare). Immuno-complexes were washed 
five times with NETN buffer (20 mM Tris, pH 8.0, 100 
mM NaCl, 1 mM EDTA and 0.5% NP-40) before being 
resolved by SDS-PAGE and immunoblotted with indicated 
antibodies. 
In vitro Kinase Assay
293T cells were transfected with Flag-
ATM constructs. Forty-eight hours later, ATM was 
immunoprecipitated using Flag-matrix (Sigma). 
Afterwards, it was incubated with 5 µg of indicated GST 
fusion proteins in the presence of 5 µCi  [γ-32P] ATP and 
20 µM cold ATP in the ATM kinase reaction buffer for 
15-30 minutes. The reaction was stopped by the addition 
of SDS-containing lysis buffer, resolved on SDS-PAGE, 
and detected by autoradiography. Casein Kinase Iδ was 
purchased from New England Biolabs. The Casein Kinase 
I in vitro kinase assay was performed according to the 
manufacturer’s instructions (New England Biolabs). 
Briefly,  5  µg  of  indicated  GST  fusion  proteins  were Oncotarget 2012; 3: 1026-1035 1034 www.impactjournals.com/oncotarget
incubated  with  purified  active  Casein  Kinase  I  in  the 
presence of 5 µCi  [γ-32P] ATP and 200 µM cold ATP in 
the Casein Kinase I reaction buffer for 15-30 minutes. The 
reaction was stopped by the addition of SDS-containing 
lysis buffer, resolved on SDS-PAGE, and detected by 
autoradiography. 
Immunofluorescence Microscopy
Cells were fixed with 4% paraformaldehyde for 10 
min, permeabilized in 0.5% Triton X-100 for 10 min, and 
incubated in PBS and 10% goat serum blocking solution 
for 1 h. The cells were incubated for 2 h with anti-CK1δ 
in 5% goat serum and were stained for 1 h with Alexa 
Fluor 594-conjugated secondary antibody (1:500). The 
slides were mounted with mounting medium containing 
antifade reagent and 4,6-diamidino-2-phenylindole. Cells 
were viewed under fluorescence microscope.
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